Adverse events (1 to 6 months post intervention) ‐ incidence of alcohol‐related consequences ‐ accidents (RR > 1 denotes greater risk) · adult patients with harmful or hazardous alcohol or substance use
It is very uncertain whether primary health professional‐ and community professional‐led… changes adverse events (1 to 6 months post intervention) ‐ incidence of… compared with enhanced usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention ATCS Plus, IVR, unidirectional ATCS versus various controls · patients/healthcare consumers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AEs; adverse drug reaction): composite neurological adverse event (confusion, vertigo, nystagmus, vomiting and diplopia) · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): composite neurological… compared with mexiletine (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (AEs) (grade 3 or 4) ‐ Network included 19 pairwise comparisons ‐ Mean risk with SUN across trials3 in this network: 70.6% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
1 finding from 1 review
Grade III–V adverse events (local adverse events which result in delay intravesical treatment were regarded as Grade III–V complications) · patients with non‐muscle invasive bladder cancer
It is very uncertain whether gemcitabine changes grade III–V adverse events (local adverse events which result in… compared with mitomycin (very low certainty).
1 finding from 1 review
Adverse events ‐ total of adverse events (various: mainly infection; cosmetic result ‐ e.g. prominent metalwork ‐ and symptomatic hardware) · adults (aged ≥ 16 years) with acute middle third clavicle fractures
It is very uncertain whether intramedullary fixation changes adverse events ‐ total of adverse events (various: mainly infection;… compared with open reduction and internal fixation with plate (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).
1 finding from 1 review
Specific serious adverse events: further surgery (device removal or revision)i assessed as: any unplanned secondary surgery to remove device · people undergoing peripheral nerve repair of the upper limb
It is very uncertain whether bioengineered devices changes specific serious adverse events: further surgery (device removal or… compared with standard techniques (very low certainty).
1 finding from 1 review
Intervention not reported
There was no evidence of differences in the number of serious adverse events for any of the comparisons Quality of evidence = very low1,2,3. · people undergoing liver resection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ acute splenic sequestration Clinical events experienced by children during the 1 year period commencing at entry to the trial · 117 children with homozygous sickle cell (SS) disease
The intervention showed no clear difference in adverse events ‐ acute splenic sequestration Clinical events… (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Behavioural outcome: adherence to medication or composite outcome (medication adherence and rate of adverse events) ATCS Plus versus usual care · patients with various conditions or at risk of low adherence to medication or laboratory tests
1 finding from 1 review
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low
Intervention not reported
Serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes serious adverse events for all placebos compared with wait‐list or… (very low certainty).
1 finding from 1 review
Adverse events (directly related to treatment, collected over the course of the studies; they are not measured/reported for specific time points) · People with fungal infections of the toenails
Tavaborole 5% solution probably leads to higher adverse events (directly related to treatment, collected over the… compared with vehicle (moderate certainty).
1 finding from 1 review
Adverse events (directly related to treatment, collected over the course of the studies; they are not measured/reported for specific time points) · People with fungal infections of the toenails
Ciclopirox 8% lacquer showed no clear difference in adverse events (directly related to treatment, collected over the… compared with vehicle (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (as defined in the primary study) Participant reports. Serious adverse events observed during double‐blind treatment period · Patients with insomnia
1 finding from 1 review
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR versus various controls · participants at risk of developing long‐term conditions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention Multimodal/complex intervention, ATCS Plus, IVR versus various controls · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found